Because effective therapies for FTLD‐TDP and ALS are urgently needed, we herein provide mechanistic insights into HDAC1 deregulation in TDP‐43 proteinopathies and outline a promising therapeutic strategy for treating FTLD‐TDP and ALS by targeting HDAC1. Here, HDAC1 is linked to amyotrophic lateral sclerosis.